,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter, September 30, 2020, was approximately $23.9 billion.",23.9,['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,mck,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, September 30, 2020, was approximately $23.9 billion.",approximately $23.9 billion,MONEY,"The aggregate market value of the voting and non voting common equity held by non affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, September 30, 2020, was approximately $23.9 billion.","['aggregate market value', 'non affiliates', 'reference to closing price', 'last business day of registrant', 'aggregate market value', 'common equity', 'non affiliates', 'closing price']","['aggregate market value of the voting and non voting common equity', 0.2163977473974228, 'What is approximately $23.9 billion ?', 'aggregate market value of the voting and non voting common equity']",aggregate market value of the voting and non voting common equity,0.2163977473974228,What is approximately $23.9 billion ?,aggregate market value of the voting and non voting common equity,common equity held by non affiliates
1,"Number of shares of common stock outstanding on April 30, 2021: 158,186,277","158,186,277","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,mck,"Number of shares of common stock outstanding on April 30, 2021: 158,186,277","158,186,277",CARDINAL,"Number of shares of common stock outstanding on April 30, 2021: 158,186,277","['Number of shares', 'shares of common outstanding stock', 'Number on April', 'common outstanding stock']","['common outstanding stock', 0.9590535759925842, 'how many common outstanding stock ?', '158,186,277']",common outstanding stock,0.9590535759925842,how many common outstanding stock ?,"158,186,277",Number of shares of common stock outstanding
2,"Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding",100,['Preferred stock authorized'],us-gaap_PreferredStockSharesAuthorized,sharesItemType,mck,"Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding",100,CARDINAL,"Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding",[],"['shares authorized', 0.9732144474983215, 'What is 100 ?', 'shares authorized']",shares authorized,0.9732144474983216,What is 100 ?,shares authorized,Preferred stock shares authorized
3,"Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding",100,['Preferred stock authorized'],us-gaap_PreferredStockSharesAuthorized,sharesItemType,mck,"Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding",100,CARDINAL,"Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding",[],"['shares authorized', 0.9732144474983215, 'What is 100 ?', 'shares authorized']",shares authorized,0.9732144474983216,What is 100 ?,shares authorized,Preferred stock authorized
4,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",800,['Common stock authorized'],us-gaap_CommonStockSharesAuthorized,sharesItemType,mck,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",800,CARDINAL,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",[],"['shares authorized', 0.9540823101997375, 'What is 800 ?', 'shares authorized']",shares authorized,0.9540823101997375,What is 800 ?,shares authorized,Shares authorized
5,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",800,['Common stock authorized'],us-gaap_CommonStockSharesAuthorized,sharesItemType,mck,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",800,CARDINAL,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",[],"['shares authorized', 0.9540823101997375, 'What is 800 ?', 'shares authorized']",shares authorized,0.9540823101997375,What is 800 ?,shares authorized,authorized shares
6,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",273,['Common stock issued'],us-gaap_CommonStockSharesIssued,sharesItemType,mck,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",273,CARDINAL,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",[],"['Common stock', 0.895418643951416, 'What is 273 ?', 'Common stock']",Common stock,0.895418643951416,What is 273 ?,Common stock,Shares of common stock issued
7,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",272,['Common stock issued'],us-gaap_CommonStockSharesIssued,sharesItemType,mck,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",272,CARDINAL,"Common stock, $0.01 par value, 800 shares authorized, 273 and 272 shares issued at March 31, 2021 and 2020, respectively",[],"['shares', 0.6380659341812134, 'What is 272 ?', 'shares']",shares,0.6380659341812134,What is 272 ?,shares,common stock shares issued
8,"Treasury shares, at cost, 115 and 110 shares at March 31, 2021 and 2020, respectively",115,['Treasury stock'],us-gaap_TreasuryStockShares,sharesItemType,mck,"Treasury shares, at cost, 115 and 110 shares at March 31, 2021 and 2020, respectively",115,CARDINAL,"Treasury shares, at cost, 115 and 110 shares at March 31, 2021 and 2020, respectively",['Treasury shares at cost'],"['Treasury shares at cost', 0.8995804786682129, 'how many Treasury shares at cost ?', '115']",Treasury shares at cost,0.8995804786682129,how many Treasury shares at cost ?,115,"Treasury shares at March 31, 2021"
9,"Treasury shares, at cost, 115 and 110 shares at March 31, 2021 and 2020, respectively",110,['Treasury stock'],us-gaap_TreasuryStockShares,sharesItemType,mck,"Treasury shares, at cost, 115 and 110 shares at March 31, 2021 and 2020, respectively",110,CARDINAL,"Treasury shares, at cost, 115 and 110 shares at March 31, 2021 and 2020, respectively",['Treasury shares at cost'],"['', 0, '', '']",,0.0,,,"Treasury shares at March 31, 2020"
10,"Nature of Operations: McKesson Corporation (""McKesson,"" or the ""Company,"") is a global provider of healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments, and other organizations in healthcare to help provide the right medicines, medical products, and healthcare services to the right patients at the right time, safely, and cost effectively. Commencing with the second quarter of 2021, the Company reports its financial results in four reportable segments: U.S. Pharmaceutical, International, Medical Surgical Solutions, and Prescription Technology Solutions (""RxTS""). All prior segment information has been recast to reflect the Company's new segment structure and current period presentation. The Company's equity method investment in Change Healthcare LLC (""Change Healthcare JV""), which was split off from McKesson in the fourth quarter of 2020, has been included in Other for retrospective periods presented. Refer to Financial Note 22, ""Segments of Business,"" for more information.",four,['Number of reportable segments'],us-gaap_NumberOfReportableSegments,integerItemType,mck,"Commencing with the second quarter of 2021, the Company reports its financial results in four reportable segments: U.S. Pharmaceutical, International, Medical Surgical Solutions, and Prescription Technology Solutions (“RxTS”).",four,CARDINAL,"Commencing with the second quarter of 2021, the Company reports its financial results in four reportable segments: U.S. Pharmaceutical, International, Medical Surgical Solutions, and Prescription Technology Solutions .","['financial results in reportable segments', 'financial results', 'reportable segments']","['financial results in reportable segments', 0.9419510364532471, 'how many financial results in reportable segments ?', 'four']",financial results in reportable segments,0.9419510364532472,how many financial results in reportable segments ?,four,reportable segments
11,"We are exposed to credit losses on accounts receivable balances. The Company estimates credit losses by considering historical credit losses, the current economic environment, customer credit ratings or bankruptcies, as well as reasonable and supportable forecasts. Management reviews these factors quarterly to determine if any adjustments are needed to the allowance. Trade accounts receivable represent the majority of the Company's financial assets, for which an allowance for credit losses of $198 million and $224 million were included in ""Receivables, net"" on the Consolidated Balance Sheet as of March 31, 2021 and 2020, respectively. Changes in the allowance were not material for the year ended March 31, 2021.",198,['Allowance for credit losses'],us-gaap_AllowanceForDoubtfulAccountsReceivable,monetaryItemType,mck,"Trade accounts receivable represent the majority of the Company's financial assets, for which an allowance for credit losses of $198 million and $224 million were included in “Receivables, net” on the Consolidated Balance Sheet as of March 31, 2021 and 2020, respectively.",$198 million and $224 million,MONEY,"Trade accounts receivable represent the majority of the Company's financial assets, for which an allowance for credit losses of $198 million and $224 million were included in “Receivables, net” on the Consolidated Balance Sheet as of March 31, 2021 and 2020, respectively.","['majority of financial assets', 'allowance', 'allowance for credit losses', 'credit losses', 'net on Consolidated Balance Sheet', 'financial assets', 'credit losses']","['credit losses', 0.7264442443847656, 'What is $198 million and $224 million ?', 'credit losses']",credit losses,0.7264442443847656,What is $198 million and $224 million ?,credit losses,"""Receivables, net"" on the Consolidated Balance Sheet"
12,"We are exposed to credit losses on accounts receivable balances. The Company estimates credit losses by considering historical credit losses, the current economic environment, customer credit ratings or bankruptcies, as well as reasonable and supportable forecasts. Management reviews these factors quarterly to determine if any adjustments are needed to the allowance. Trade accounts receivable represent the majority of the Company's financial assets, for which an allowance for credit losses of $198 million and $224 million were included in ""Receivables, net"" on the Consolidated Balance Sheet as of March 31, 2021 and 2020, respectively. Changes in the allowance were not material for the year ended March 31, 2021.",224,['Allowance for credit losses'],us-gaap_AllowanceForDoubtfulAccountsReceivable,monetaryItemType,mck,"Trade accounts receivable represent the majority of the Company's financial assets, for which an allowance for credit losses of $198 million and $224 million were included in “Receivables, net” on the Consolidated Balance Sheet as of March 31, 2021 and 2020, respectively.",$198 million and $224 million,MONEY,"Trade accounts receivable represent the majority of the Company's financial assets, for which an allowance for credit losses of $198 million and $224 million were included in “Receivables, net” on the Consolidated Balance Sheet as of March 31, 2021 and 2020, respectively.","['majority of financial assets', 'allowance', 'allowance for credit losses', 'credit losses', 'net on Consolidated Balance Sheet', 'financial assets', 'credit losses']","['credit losses', 0.7264442443847656, 'What is $198 million and $224 million ?', 'credit losses']",credit losses,0.7264442443847656,What is $198 million and $224 million ?,credit losses,"""Receivables, net"" on the Consolidated Balance Sheet"
13,"Concentrations of Credit Risk and Receivables: The Company's trade accounts receivable are subject to concentrations of credit risk with customers primarily in its U.S. Pharmaceutical segment. During 2021, sales to the Company's ten largest customers, including group purchasing organizations (""GPOs""), accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021. Sales to the Company's largest customer, CVS Health Corporation (""CVS""), accounted for approximately 21% of its total consolidated revenues in 2021 and comprised approximately 19% of total trade accounts receivable at March 31, 2021. As a result, the Company's sales and credit concentration is significant. The Company has agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies and other healthcare providers, as well as with government entities and agencies. The accounts receivables balances are with individual members of the GPOs, and therefore no significant concentration of credit risk exists. A material default in payment, a material reduction in purchases from these or any other large customers, or the loss of a large customer or customer groups could have a material adverse impact on the Company's financial condition, results of operations, and liquidity. In addition, trade receivables are subject to concentrations of credit risk with customers in the institutional, retail, and healthcare provider sectors, which can be affected by a downturn in the economy and changes in reimbursement policies. This credit risk is mitigated by the size and diversity of the Company's customer base as well as its geographic dispersion.",ten,['Number of largest customers'],mck_NumberofLargestCustomers,integerItemType,mck,"During 2021, sales to the Company’s ten largest customers, including group purchasing organizations (“GPOs”), accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021.",ten,CARDINAL,"During 2021, sales to the Company’s ten largest customers, including group purchasing organizations , accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021.","['sales to largest customers', '% of total consolidated revenues', 'receivable % of total trade accounts', 'largest customers', 'group purchasing organizations', 'total consolidated revenues', 'total trade accounts']","['sales to largest customers', 0.8989211916923523, 'how many sales to largest customers ?', 'ten']",sales to largest customers,0.8989211916923523,how many sales to largest customers ?,ten,largest customers
14,"Concentrations of Credit Risk and Receivables: The Company's trade accounts receivable are subject to concentrations of credit risk with customers primarily in its U.S. Pharmaceutical segment. During 2021, sales to the Company's ten largest customers, including group purchasing organizations (""GPOs""), accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021. Sales to the Company's largest customer, CVS Health Corporation (""CVS""), accounted for approximately 21% of its total consolidated revenues in 2021 and comprised approximately 19% of total trade accounts receivable at March 31, 2021. As a result, the Company's sales and credit concentration is significant. The Company has agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies and other healthcare providers, as well as with government entities and agencies. The accounts receivables balances are with individual members of the GPOs, and therefore no significant concentration of credit risk exists. A material default in payment, a material reduction in purchases from these or any other large customers, or the loss of a large customer or customer groups could have a material adverse impact on the Company's financial condition, results of operations, and liquidity. In addition, trade receivables are subject to concentrations of credit risk with customers in the institutional, retail, and healthcare provider sectors, which can be affected by a downturn in the economy and changes in reimbursement policies. This credit risk is mitigated by the size and diversity of the Company's customer base as well as its geographic dispersion.",51,['Percentage of total consolidated revenues'],us-gaap_ConcentrationRiskPercentage1,percentItemType,mck,"During 2021, sales to the Company’s ten largest customers, including group purchasing organizations (“GPOs”), accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021.",approximately 51%,PERCENT,"During 2021, sales to the Company’s ten largest customers, including group purchasing organizations , accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021.","['sales to largest customers', '% of total consolidated revenues', 'receivable % of total trade accounts', 'largest customers', 'group purchasing organizations', 'total consolidated revenues', 'total trade accounts']","['', 0, '', '']",,0.0,,,"total consolidated revenues

Entity:
approximately 32%
Phrase:
total trade accounts receivable"
15,"Concentrations of Credit Risk and Receivables: The Company's trade accounts receivable are subject to concentrations of credit risk with customers primarily in its U.S. Pharmaceutical segment. During 2021, sales to the Company's ten largest customers, including group purchasing organizations (""GPOs""), accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021. Sales to the Company's largest customer, CVS Health Corporation (""CVS""), accounted for approximately 21% of its total consolidated revenues in 2021 and comprised approximately 19% of total trade accounts receivable at March 31, 2021. As a result, the Company's sales and credit concentration is significant. The Company has agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies and other healthcare providers, as well as with government entities and agencies. The accounts receivables balances are with individual members of the GPOs, and therefore no significant concentration of credit risk exists. A material default in payment, a material reduction in purchases from these or any other large customers, or the loss of a large customer or customer groups could have a material adverse impact on the Company's financial condition, results of operations, and liquidity. In addition, trade receivables are subject to concentrations of credit risk with customers in the institutional, retail, and healthcare provider sectors, which can be affected by a downturn in the economy and changes in reimbursement policies. This credit risk is mitigated by the size and diversity of the Company's customer base as well as its geographic dispersion.",32,['Percentage of total consolidated revenues'],us-gaap_ConcentrationRiskPercentage1,percentItemType,mck,"During 2021, sales to the Company’s ten largest customers, including group purchasing organizations (“GPOs”), accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021.",approximately 32%,PERCENT,"During 2021, sales to the Company’s ten largest customers, including group purchasing organizations , accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021.","['sales to largest customers', '% of total consolidated revenues', 'receivable % of total trade accounts', 'largest customers', 'group purchasing organizations', 'total consolidated revenues', 'total trade accounts']","['total trade accounts', 0.36354759335517883, 'What is approximately 32% ?', 'total trade accounts']",total trade accounts,0.3635475933551788,What is approximately 32% ?,total trade accounts,total trade accounts receivable
16,"Concentrations of Credit Risk and Receivables: The Company's trade accounts receivable are subject to concentrations of credit risk with customers primarily in its U.S. Pharmaceutical segment. During 2021, sales to the Company's ten largest customers, including group purchasing organizations (""GPOs""), accounted for approximately 51% of its total consolidated revenues and approximately 32% of total trade accounts receivable at March 31, 2021. Sales to the Company's largest customer, CVS Health Corporation (""CVS""), accounted for approximately 21% of its total consolidated revenues in 2021 and comprised approximately 19% of total trade accounts receivable at March 31, 2021. As a result, the Company's sales and credit concentration is significant. The Company has agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies and other healthcare providers, as well as with government entities and agencies. The accounts receivables balances are with individual members of the GPOs, and therefore no significant concentration of credit risk exists. A material default in payment, a material reduction in purchases from these or any other large customers, or the loss of a large customer or customer groups could have a material adverse impact on the Company's financial condition, results of operations, and liquidity. In addition, trade receivables are subject to concentrations of credit risk with customers in the institutional, retail, and healthcare provider sectors, which can be affected by a downturn in the economy and changes in reimbursement policies. This credit risk is mitigated by the size and diversity of the Company's customer base as well as its geographic dispersion.",19,['Percentage of total consolidated revenues'],us-gaap_ConcentrationRiskPercentage1,percentItemType,mck,"Sales to the Company’s largest customer, CVS Health Corporation (“CVS”), accounted for approximately 21% of its total consolidated revenues in 2021 and comprised approximately 19% of total trade accounts receivable at March 31, 2021.",approximately 19%,PERCENT,"Sales to the Company’s largest customer, CVS Health Corporation , accounted for approximately 21% of its total consolidated revenues in 2021 and comprised approximately 19% of total trade accounts receivable at March 31, 2021.","['Sales to CVS Health Corporation', '% of total consolidated revenues', '% of total trade accounts', 'total consolidated revenues', 'total trade accounts']","['trade accounts', 0.3813166618347168, 'What is approximately 19% ?', 'trade accounts']",trade accounts,0.3813166618347168,What is approximately 19% ?,trade accounts,of total trade accounts receivable
17,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",58,['LIFO inventory'],us-gaap_PercentageOfLIFOInventory,percentItemType,mck,"The LIFO method was used to value approximately 58% and 60% of the Company’s inventories at March 31, 2021 and 2020, respectively.",approximately 58% and 60%,PERCENT,"The LIFO method was used to value approximately 58% and 60% of the Company’s inventories at March 31, 2021 and 2020, respectively.","['% of inventories', 'LIFO method']","['LIFO method', 0.5963712930679321, 'What is approximately 58% and 60% ?', 'LIFO method']",LIFO method,0.5963712930679321,What is approximately 58% and 60% ?,LIFO method,the Company's inventories
18,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",60,['LIFO inventory'],us-gaap_PercentageOfLIFOInventory,percentItemType,mck,"The LIFO method was used to value approximately 58% and 60% of the Company’s inventories at March 31, 2021 and 2020, respectively.",approximately 58% and 60%,PERCENT,"The LIFO method was used to value approximately 58% and 60% of the Company’s inventories at March 31, 2021 and 2020, respectively.","['% of inventories', 'LIFO method']","['LIFO method', 0.5963712930679321, 'What is approximately 58% and 60% ?', 'LIFO method']",LIFO method,0.5963712930679321,What is approximately 58% and 60% ?,LIFO method,the Company's inventories
19,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",406,['LIFO reserve'],us-gaap_InventoryLIFOReserve,monetaryItemType,mck,"If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively.",approximately $406 million and $444 million,MONEY,"If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively.","['moving average method of inventory valuation', 'average method', 'inventory valuation']","['inventories', 0.9904114603996277, 'What is approximately $406 million and $444 million ?', 'inventories']",inventories,0.9904114603996276,What is approximately $406 million and $444 million ?,inventories,moving average method of inventory valuation
20,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",444,['LIFO reserve'],us-gaap_InventoryLIFOReserve,monetaryItemType,mck,"If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively.",approximately $406 million and $444 million,MONEY,"If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively.","['moving average method of inventory valuation', 'average method', 'inventory valuation']","['inventories', 0.9904114603996277, 'What is approximately $406 million and $444 million ?', 'inventories']",inventories,0.9904114603996276,What is approximately $406 million and $444 million ?,inventories,higher than the amounts reported
21,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",38,"['Credits associated with last in, first out inventory method']",us-gaap_InventoryLIFOReservePeriodCharge,monetaryItemType,mck,"The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in “Cost of sales” in its Consolidated Statements of Operations.",$38 million,MONEY,"The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in “Cost of sales” in its Consolidated Statements of Operations.","['LIFO credits', 'Cost of sales', 'Cost in Consolidated Statements', 'LIFO credits']","['LIFO credits', 0.8923407196998596, 'What is $38 million ?', 'LIFO credits']",LIFO credits,0.8923407196998596,What is $38 million ?,LIFO credits,"LIFO credits in ""Cost of sales"""
22,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",252,"['Credits associated with last in, first out inventory method']",us-gaap_InventoryLIFOReservePeriodCharge,monetaryItemType,mck,"The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in “Cost of sales” in its Consolidated Statements of Operations.",$252 million,MONEY,"The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in “Cost of sales” in its Consolidated Statements of Operations.","['LIFO credits', 'Cost of sales', 'Cost in Consolidated Statements', 'LIFO credits']","['LIFO credits', 0.7015363574028015, 'What is $252 million ?', 'LIFO credits']",LIFO credits,0.7015363574028015,What is $252 million ?,LIFO credits,"LIFO credits in ""Cost of sales"""
23,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",210,"['Credits associated with last in, first out inventory method']",us-gaap_InventoryLIFOReservePeriodCharge,monetaryItemType,mck,"The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in “Cost of sales” in its Consolidated Statements of Operations.",$210 million,MONEY,"The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in “Cost of sales” in its Consolidated Statements of Operations.","['LIFO credits', 'Cost of sales', 'Cost in Consolidated Statements', 'LIFO credits']","['', 0, '', '']",,0.0,,,Recognized LIFO credits
24,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",263,['Inventory valuation reserves'],us-gaap_InventoryValuationReserves,monetaryItemType,mck,"Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively.",$263 million,MONEY,"Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively.","['inventory reserves', 'LIFO reserves', 'inventory reserves']","['LIFO reserves', 0.11539234220981598, 'What is $263 million ?', 'LIFO reserves']",LIFO reserves,0.1153923422098159,What is $263 million ?,LIFO reserves,Inventory reserves
25,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",96,['Inventory valuation reserves'],us-gaap_InventoryValuationReserves,monetaryItemType,mck,"Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively.",$96 million,MONEY,"Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively.","['inventory reserves', 'LIFO reserves', 'inventory reserves']","['Excluding LIFO reserves', 0.15310461819171906, 'What is $96 million ?', 'Excluding LIFO reserves']",Excluding LIFO reserves,0.153104618191719,What is $96 million ?,Excluding LIFO reserves,Inventory reserves
26,"The LIFO method was used to value approximately 58% and 60% of the Company's inventories at March 31, 2021 and 2020, respectively. If the Company had used the moving average method of inventory valuation, inventories would have been approximately $406 million and $444 million higher than the amounts reported at March 31, 2021 and 2020, respectively. These amounts are equivalent to the Company's LIFO reserves. The Company's LIFO valuation amount includes both pharmaceutical and non pharmaceutical products. The Company recognized LIFO credits of $38 million, $252 million, and $210 million in 2021, 2020, and 2019, respectively, in ""Cost of sales"" in its Consolidated Statements of Operations. The lower LIFO credits in 2021 compared to 2020 is primarily due to higher brand inflation and delays of branded off patent to generic drug launches. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non pharmaceutical products held in inventory. Excluding LIFO reserves, inventory reserves as of March 31, 2021 and 2020 were $263 million and $96 million, respectively. The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment. These charges are recorded in ""Cost of sales"" in the Consolidated Statements of Operations.",136,['Inventory write down charges'],us-gaap_InventoryWriteDown,monetaryItemType,mck,The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment.,$136 million,MONEY,The increase was primarily due to charges in 2021 totaling $136 million on certain personal protective equipment and other related products due to inventory impairments and excess inventory within our Medical Surgical Solutions segment.,"['charges', 'inventory impairments within Solutions segment', 'certain personal protective equipment', 'inventory impairments', 'Solutions segment']","['personal protective equipment', 0.4545215368270874, 'What is $136 million ?', 'personal protective equipment']",personal protective equipment,0.4545215368270874,What is $136 million ?,personal protective equipment,Certain personal protective equipment
27,"Shipping and Handling Costs: The Company includes costs to pack and deliver inventory to its customers in Selling, distribution, general, and administrative expenses. Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",1.0,['Shipping and handling costs'],us-gaap_SellingGeneralAndAdministrativeExpense,monetaryItemType,mck,"Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",$1.0 billion,MONEY,"Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",['costs'],"['Shipping and handling costs', 0.8134709000587463, 'What is $1.0 billion ?', 'Shipping and handling costs']",Shipping and handling costs,0.8134709000587463,What is $1.0 billion ?,Shipping and handling costs,Shipping and handling costs
28,"Shipping and Handling Costs: The Company includes costs to pack and deliver inventory to its customers in Selling, distribution, general, and administrative expenses. Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",1.0,['Shipping and handling costs'],us-gaap_SellingGeneralAndAdministrativeExpense,monetaryItemType,mck,"Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",$1.0 billion,MONEY,"Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",['costs'],"['Shipping and handling costs', 0.8134709000587463, 'What is $1.0 billion ?', 'Shipping and handling costs']",Shipping and handling costs,0.8134709000587463,What is $1.0 billion ?,Shipping and handling costs,Shipping and handling costs
29,"Shipping and Handling Costs: The Company includes costs to pack and deliver inventory to its customers in Selling, distribution, general, and administrative expenses. Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",951,['Shipping and handling costs'],us-gaap_SellingGeneralAndAdministrativeExpense,monetaryItemType,mck,"Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",$951 million,MONEY,"Shipping and handling costs of $1.0 billion, $1.0 billion, and $951 million were recognized in 2021, 2020, and 2019, respectively.",['costs'],"['Shipping and handling costs', 0.2813665270805359, 'What is $951 million ?', 'Shipping and handling costs']",Shipping and handling costs,0.2813665270805359,What is $951 million ?,Shipping and handling costs,Shipping and handling costs
30,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other. Leasehold improvements and property, plant, and equipment, net under finance leases are amortized over their respective useful lives or over the term of the lease, whichever is shorter. Depreciation and amortization begins when an asset is placed in service and ready for its intended use. Repairs and maintenance costs are expensed as incurred. When certain events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable, an impairment assessment may be performed on the recoverability of the carrying amounts.",15,"['Property, plant and equipment, useful life']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,mck,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.",15 to 30 years,DATE,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.","['straight line method over estimated useful life', 'estimated useful life of asset', 'years for building', 'years for machinery', 'historical cost', 'straight line method', 'useful life']","['building and improvements', 0.8677516579627991, 'What is 15 to 30 years ?', 'building and improvements']",building and improvements,0.8677516579627991,What is 15 to 30 years ?,building and improvements,Useful life of each asset
31,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other. Leasehold improvements and property, plant, and equipment, net under finance leases are amortized over their respective useful lives or over the term of the lease, whichever is shorter. Depreciation and amortization begins when an asset is placed in service and ready for its intended use. Repairs and maintenance costs are expensed as incurred. When certain events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable, an impairment assessment may be performed on the recoverability of the carrying amounts.",30,"['Property, plant and equipment, useful life']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,mck,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.",15 to 30 years,DATE,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.","['straight line method over estimated useful life', 'estimated useful life of asset', 'years for building', 'years for machinery', 'historical cost', 'straight line method', 'useful life']","['building and improvements', 0.8677516579627991, 'What is 15 to 30 years ?', 'building and improvements']",building and improvements,0.8677516579627991,What is 15 to 30 years ?,building and improvements,Useful life of each asset
32,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other. Leasehold improvements and property, plant, and equipment, net under finance leases are amortized over their respective useful lives or over the term of the lease, whichever is shorter. Depreciation and amortization begins when an asset is placed in service and ready for its intended use. Repairs and maintenance costs are expensed as incurred. When certain events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable, an impairment assessment may be performed on the recoverability of the carrying amounts.",3,"['Property, plant and equipment, useful life']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,mck,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.",15 to 30 years,DATE,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.","['straight line method over estimated useful life', 'estimated useful life of asset', 'years for building', 'years for machinery', 'historical cost', 'straight line method', 'useful life']","['building and improvements', 0.8677516579627991, 'What is 15 to 30 years ?', 'building and improvements']",building and improvements,0.8677516579627991,What is 15 to 30 years ?,building and improvements,Useful life of each asset
33,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other. Leasehold improvements and property, plant, and equipment, net under finance leases are amortized over their respective useful lives or over the term of the lease, whichever is shorter. Depreciation and amortization begins when an asset is placed in service and ready for its intended use. Repairs and maintenance costs are expensed as incurred. When certain events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable, an impairment assessment may be performed on the recoverability of the carrying amounts.",15,"['Property, plant and equipment, useful life']",us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,mck,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.",15 to 30 years,DATE,"Property, Plant, and Equipment, Net: Property, plant, and equipment, net is stated at historical cost and depreciated under the straight line method over the estimated useful life of each asset, which ranges from 15 to 30 years for building and improvements and 3 to 15 years for machinery, equipment, and other.","['straight line method over estimated useful life', 'estimated useful life of asset', 'years for building', 'years for machinery', 'historical cost', 'straight line method', 'useful life']","['building and improvements', 0.8677516579627991, 'What is 15 to 30 years ?', 'building and improvements']",building and improvements,0.8677516579627991,What is 15 to 30 years ?,building and improvements,Useful life of each asset
34,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.",344,['Depreciation'],us-gaap_DepreciationDepletionAndAmortization,monetaryItemType,mck,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.",$344 million,MONEY,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.","['Total depreciation expense for property', 'equipment of finance leases', 'Total depreciation expense', 'finance leases']","['Total depreciation expense for property', 0.49223923683166504, 'what is Total depreciation expense for property ?', '$344 million']",Total depreciation expense for property,0.492239236831665,what is Total depreciation expense for property ?,$344 million,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases."
35,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.",335,['Depreciation'],us-gaap_DepreciationDepletionAndAmortization,monetaryItemType,mck,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.",$335 million,MONEY,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.","['Total depreciation expense for property', 'equipment of finance leases', 'Total depreciation expense', 'finance leases']","['amortization of finance leases', 0.20192687213420868, 'What is $335 million ?', 'amortization of finance leases']",amortization of finance leases,0.2019268721342086,What is $335 million ?,amortization of finance leases,"Depreciation expense for property, plant, and equipment"
36,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.",317,['Depreciation'],us-gaap_DepreciationDepletionAndAmortization,monetaryItemType,mck,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.",$317 million,MONEY,"Total depreciation expense for property, plant, and equipment, net and amortization of finance leases was $344 million, $335 million, and $317 million for the years ended March 31, 2021, 2020, and 2019, respectively.","['Total depreciation expense for property', 'equipment of finance leases', 'Total depreciation expense', 'finance leases']","['', 0, '', '']",,0.0,,,"Depreciation expense for property, plant, and equipment"
37,"Intangible Assets: Currently all of the Company's intangible assets are subject to amortization and are amortized based on the pattern of their economic consumption or on a straight line basis over their estimated useful lives, ranging from one to 38 years. The Company reviews intangible assets for impairment at an asset group level whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated future undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset group over its estimated fair market value.",38,"['Intangible assets, useful life']",us-gaap_FiniteLivedIntangibleAssetUsefulLife,durationItemType,mck,"Intangible Assets: Currently all of the Company’s intangible assets are subject to amortization and are amortized based on the pattern of their economic consumption or on a straight line basis over their estimated useful lives, ranging from one to 38 years.",one to 38 years,DATE,"Intangible Assets: Currently all of the Company’s intangible assets are subject to amortization and are amortized based on the pattern of their economic consumption or on a straight line basis over their estimated useful lives, ranging from one to 38 years.","['pattern of economic consumption', 'line basis over estimated useful lives', 'intangible assets', 'economic consumption', 'line basis', 'useful lives']","['line basis over estimated useful lives', 0.2934253215789795, 'what is line basis over estimated useful lives ?', 'one to 38 years']",line basis over estimated useful lives,0.2934253215789795,what is line basis over estimated useful lives ?,one to 38 years,Intangible Assets amortization
38,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",10,"['Capitalized software held for internal use, useful life']",mck_CapitalizedSoftwareHeldforInternalUseUsefulLife,durationItemType,mck,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years.",10 years,DATE,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years.","['costs of software', 'development stage of project', 'Capitalized Software', 'Internal Use', 'internal use', 'development stage', 'straight line method', 'useful lives']","['costs of software', 0.22645539045333862, 'what is costs of software ?', 'not to exceed 10 years']",costs of software,0.2264553904533386,what is costs of software ?,not to exceed 10 years,The Company's software development project
39,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",513,"['Capitalized software held for internal use, net']",us-gaap_CapitalizedComputerSoftwareNet,monetaryItemType,mck,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.",$513 million and $400 million,MONEY,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.","['net of accumulated amortization', 'accumulated amortization', 'Other non current assets in Consolidated Balance Sheets', 'internal use', 'Other non current assets']","['capitalized software held for internal use', 0.6084451079368591, 'What is $513 million and $400 million ?', 'capitalized software held for internal use']",capitalized software held for internal use,0.6084451079368591,What is $513 million and $400 million ?,capitalized software held for internal use,Capitalized software held for internal use
40,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",400,"['Capitalized software held for internal use, net']",us-gaap_CapitalizedComputerSoftwareNet,monetaryItemType,mck,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.",$513 million and $400 million,MONEY,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.","['net of accumulated amortization', 'accumulated amortization', 'Other non current assets in Consolidated Balance Sheets', 'internal use', 'Other non current assets']","['capitalized software held for internal use', 0.6084451079368591, 'What is $513 million and $400 million ?', 'capitalized software held for internal use']",capitalized software held for internal use,0.6084451079368591,What is $513 million and $400 million ?,capitalized software held for internal use,Capitalized software held for internal use
41,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",1.4,"['Capitalized software held for internal use, accumulated amortization']",us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization,monetaryItemType,mck,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.",$1.4 billion,MONEY,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.","['net of accumulated amortization', 'accumulated amortization', 'Other non current assets in Consolidated Balance Sheets', 'internal use', 'Other non current assets']","['net of accumulated amortization', 0.7287485003471375, 'what is net of accumulated amortization ?', '$1.4 billion']",net of accumulated amortization,0.7287485003471375,what is net of accumulated amortization ?,$1.4 billion,Capitalized software held for internal use
42,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",1.3,"['Capitalized software held for internal use, accumulated amortization']",us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization,monetaryItemType,mck,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.",$1.3 billion,MONEY,"As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in “Other non current assets” in the Consolidated Balance Sheets.","['net of accumulated amortization', 'accumulated amortization', 'Other non current assets in Consolidated Balance Sheets', 'internal use', 'Other non current assets']","['net of accumulated amortization', 0.3687557876110077, 'What is $1.3 billion ?', 'net of accumulated amortization']",net of accumulated amortization,0.3687557876110077,What is $1.3 billion ?,net of accumulated amortization,Accumulated amortization of capitalized software
43,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",117,"['Capitalized software held for internal use, amortization']",us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,mck,"Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",$117 million,MONEY,"Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.","['Amortization expense for capitalized software', 'Amortization expense', 'internal use']","['Amortization expense for capitalized software', 0.47763291001319885, 'what is Amortization expense for capitalized software ?', '$117 million, $129 million']",Amortization expense for capitalized software,0.4776329100131988,what is Amortization expense for capitalized software ?,"$117 million, $129 million",Amortization expense for capitalized software
44,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",129,"['Capitalized software held for internal use, amortization']",us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,mck,"Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",$129 million,MONEY,"Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.","['Amortization expense for capitalized software', 'Amortization expense', 'internal use']","['Amortization expense for capitalized software', 0.47763291001319885, 'what is Amortization expense for capitalized software ?', '$117 million, $129 million']",Amortization expense for capitalized software,0.4776329100131988,what is Amortization expense for capitalized software ?,"$117 million, $129 million",Amortization expense for capitalized software
45,"Capitalized Software Held for Internal Use: The Company capitalizes costs of software held for internal use during the application development stage of a project and amortizes those costs using the straight line method over their estimated useful lives, not to exceed 10 years. As of March 31, 2021 and 2020, capitalized software held for internal use was $513 million and $400 million, respectively, net of accumulated amortization of $1.4 billion and $1.3 billion, respectively, and is included in ""Other non current assets"" in the Consolidated Balance Sheets. Costs incurred during the preliminary project and post implementation stages are expensed as incurred. Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",137,"['Capitalized software held for internal use, amortization']",us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,mck,"Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.",$137 million,MONEY,"Amortization expense for capitalized software held for internal use was $117 million, $129 million, and $137 million for the years ended March 31, 2021, 2020, and 2019, respectively.","['Amortization expense for capitalized software', 'Amortization expense', 'internal use']","['', 0, '', '']",,0.0,,,Amortization expense for capitalized software
46,"Revenues generated from the distribution of pharmaceutical and medical products represent the majority of the Company's revenues. The Company orders product from the manufacturer, receives and carries the product at its central distribution facilities, and delivers the product directly to its customers' warehouses, hospitals, or retail pharmacies. The distribution business primarily generates revenue from a contract related to a confirmed purchase order with a customer in a distribution arrangement. Revenue is recognized when control of goods is transferred to the customer which occurs upon the Company's delivery to the customer or upon customer pick up. The Company also earns revenues from a variety of other sources including its retail, services, and technology businesses. Retail revenues are recognized at the point of sale. Service revenues, including technology service revenues, are recognized when services are rendered. Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",98,['Percentage of total consolidated revenues'],us-gaap_ConcentrationRiskPercentage1,percentItemType,mck,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",approximately 98% and 2%,PERCENT,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.","['point of sale', '% of total revenues', 'total revenues']","['revenues derived from services', 0.891423761844635, 'What is approximately 98% and 2% ?', 'revenues derived from services']",revenues derived from services,0.891423761844635,What is approximately 98% and 2% ?,revenues derived from services,"total revenues for each of the years ended March 31, 2021 and 2020, respectively"
47,"Revenues generated from the distribution of pharmaceutical and medical products represent the majority of the Company's revenues. The Company orders product from the manufacturer, receives and carries the product at its central distribution facilities, and delivers the product directly to its customers' warehouses, hospitals, or retail pharmacies. The distribution business primarily generates revenue from a contract related to a confirmed purchase order with a customer in a distribution arrangement. Revenue is recognized when control of goods is transferred to the customer which occurs upon the Company's delivery to the customer or upon customer pick up. The Company also earns revenues from a variety of other sources including its retail, services, and technology businesses. Retail revenues are recognized at the point of sale. Service revenues, including technology service revenues, are recognized when services are rendered. Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",98,['Percentage of total consolidated revenues'],us-gaap_ConcentrationRiskPercentage1,percentItemType,mck,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",approximately 98% and 2%,PERCENT,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.","['point of sale', '% of total revenues', 'total revenues']","['revenues derived from services', 0.891423761844635, 'What is approximately 98% and 2% ?', 'revenues derived from services']",revenues derived from services,0.891423761844635,What is approximately 98% and 2% ?,revenues derived from services,"total revenues for each of the years ended March 31, 2021 and 2020"
48,"Revenues generated from the distribution of pharmaceutical and medical products represent the majority of the Company's revenues. The Company orders product from the manufacturer, receives and carries the product at its central distribution facilities, and delivers the product directly to its customers' warehouses, hospitals, or retail pharmacies. The distribution business primarily generates revenue from a contract related to a confirmed purchase order with a customer in a distribution arrangement. Revenue is recognized when control of goods is transferred to the customer which occurs upon the Company's delivery to the customer or upon customer pick up. The Company also earns revenues from a variety of other sources including its retail, services, and technology businesses. Retail revenues are recognized at the point of sale. Service revenues, including technology service revenues, are recognized when services are rendered. Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",2,['Percentage of total consolidated revenues'],us-gaap_ConcentrationRiskPercentage1,percentItemType,mck,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",approximately 98% and 2%,PERCENT,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.","['point of sale', '% of total revenues', 'total revenues']","['revenues derived from services', 0.891423761844635, 'What is approximately 98% and 2% ?', 'revenues derived from services']",revenues derived from services,0.891423761844635,What is approximately 98% and 2% ?,revenues derived from services,"total revenues for each of the years ended March 31, 2021 and 2020, respectively."
49,"Revenues generated from the distribution of pharmaceutical and medical products represent the majority of the Company's revenues. The Company orders product from the manufacturer, receives and carries the product at its central distribution facilities, and delivers the product directly to its customers' warehouses, hospitals, or retail pharmacies. The distribution business primarily generates revenue from a contract related to a confirmed purchase order with a customer in a distribution arrangement. Revenue is recognized when control of goods is transferred to the customer which occurs upon the Company's delivery to the customer or upon customer pick up. The Company also earns revenues from a variety of other sources including its retail, services, and technology businesses. Retail revenues are recognized at the point of sale. Service revenues, including technology service revenues, are recognized when services are rendered. Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",2,['Percentage of total consolidated revenues'],us-gaap_ConcentrationRiskPercentage1,percentItemType,mck,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.",approximately 98% and 2%,PERCENT,"Revenues derived from distribution and retail business at the point of sale, and revenues derived from services represent approximately 98% and 2% of total revenues for each of the years ended March 31, 2021 and 2020, respectively.","['point of sale', '% of total revenues', 'total revenues']","['revenues derived from services', 0.891423761844635, 'What is approximately 98% and 2% ?', 'revenues derived from services']",revenues derived from services,0.891423761844635,What is approximately 98% and 2% ?,revenues derived from services,"total revenues for each of the years ended March 31, 2021 and 2020"
